Background
- Epstein-Barr virus associated gastric cancer (EBVaGC) is found in ~9% of GC and is associated with a unique immunophenotype1.
- Prior studies suggest 15-100% objective response rates (ORR) to immune checkpoint inhibition (ICI), but survival outcomes are limited by small cohort size2,3,4.
- This study sought to clarify outcomes of ICI in EBVaGC across 9 global tertiary cancer centers, evaluate if next-generation sequencing (NGS) can replace EBER ISH as the gold standard for detection, and identify features of ICI-responsive EBVaGC.